Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
42.63
+0.68 (+1.62%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
33
34
Next >
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Preview: GlaxoSmithKline's Earnings
January 31, 2023
Via
Benzinga
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
January 30, 2023
Via
Benzinga
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
January 30, 2023
But Moderna stock didn't move higher on the announcement.
Via
Investor's Business Daily
How Could GSK's RSV Vaccine Change its Valuation?
January 26, 2023
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.
Via
MarketBeat
Exposures
Product Safety
Earnings Preview: GSK Q4 Earnings Expected To Decline
January 25, 2023
This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%.
Via
Talk Markets
GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know
January 23, 2023
Via
Benzinga
3 Penny Stocks That Could Make You Filthy Rich
January 25, 2023
These low-priced equities could deliver enormous returns for risk-tolerant shareholders.
Via
The Motley Fool
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
January 24, 2023
Via
Benzinga
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
January 21, 2023
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.
Via
The Motley Fool
Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review
January 20, 2023
Microsoft and Google are slashing jobs. Netflix and Tesla jumped.
Via
Investor's Business Daily
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
January 19, 2023
After years of lab failures, the companies could crack open a multibillion-dollar market.
Via
Investor's Business Daily
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy'
January 18, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."
Via
Benzinga
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
January 18, 2023
Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday.
Via
Benzinga
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
January 17, 2023
Moderna is stepping up to Pfizer and GSK, both of which are developing RSV vaccines.
Via
Investor's Business Daily
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
January 07, 2023
WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to...
Via
Talk Markets
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
January 06, 2023
CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.
Via
InvestorPlace
The Year of the Tripledemic
January 03, 2023
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which...
Via
TheNewswire.com
Topics
Death
Exposures
COVID-19
Death
Product Safety
The Year of the Tripledemic
January 03, 2023
The Year of the Tripledemic
Via
News Direct
Topics
Death
Exposures
COVID-19
Death
What You Missed On Wall Street On Friday
December 31, 2022
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.
Via
Talk Markets
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'
Via
Benzinga
Big Health Care Stocks to Watch in the New Year
December 29, 2022
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.
Via
MarketBeat
7 Drug Stocks That Will Soar in 2023
December 22, 2022
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.
Via
InvestorPlace
2 Smartest Tech Stocks to Buy in 2022 and Beyond
December 20, 2022
The tech space is still bursting with opportunities for long-term investors.
Via
The Motley Fool
Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says
December 14, 2022
Via
Benzinga
Options Trader Betting On GSK Stock Rising Heading Into 2023
December 13, 2022
Options traders are making big bets on the upside for healthcare, particularly in shares of GSK plc (NYSE: GSK).
Via
Benzinga
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
December 13, 2022
Via
Benzinga
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
December 13, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
December 11, 2022
From
GSK plc
Via
Business Wire
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
December 09, 2022
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.
Via
MarketBeat
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.